A structural explanation for statin muscle toxicity emerges
Statins have long sat at the center of cardiovascular prevention because they lower cholesterol and cut the risk of heart attack and stroke. For many patients, though, the benefit has carried an unwelcome price: muscle pain, weakness, fatigue, and in a small number of cases severe muscle breakdown that can threaten kidney function. The new work from the University of British Columbia and collaborators at the University of Wisconsin-Madison gives that adverse effect a concrete molecular address.
Using cryo-electron microscopy, investigators mapped how statin molecules interact with the ryanodine receptor 1 (RyR1), a calcium channel that governs muscle contraction. Under normal physiology, RyR1 opens and closes with precision so that calcium is released when a muscle fiber needs to contract and then withdrawn again. The structural data show a different outcome when statins bind: the channel is nudged into an open state, allowing calcium to leak continuously into areas where it should remain tightly controlled.
The result is not subtle. Persistent calcium leak is the kind of intracellular disturbance that can erode muscle integrity over time, producing the aches and weakness patients recognize at the bedside. In more severe cases, the same disruption may contribute to muscle injury serious enough to raise concern for kidney damage.
Three atorvastatin molecules and one vulnerable channel
The study focused on atorvastatin, one of the most widely prescribed members of the statin class. The investigators observed an unusual sequence of binding events inside the RyR1 pocket: one statin molecule first attaches while the channel is closed, making opening more likely, and two additional molecules then occupy the same region and hold the channel in an open conformation. That triplet arrangement is the heart of the mechanism.
The detail matters because it moves the discussion beyond a vague intolerance signal. Statin-associated myalgias have often been discussed as a class effect without a precise structural explanation. Here, the channel itself becomes the culprit site, and the calcium leak becomes the biologic bridge between a cholesterol drug and damaged skeletal muscle.
“Statins have been a cornerstone of cardiovascular care for decades,” said senior author Dr. Filip Van Petegem, professor at UBC’s Life Sciences Institute. The practical implication is straightforward: if a future statin can be engineered so it no longer fits this RyR1 pocket, cholesterol lowering may be preserved while muscle exposure is reduced.
That is where the science turns translational. Drug design can now target the molecular shape responsible for the off-target effect instead of relying on trial and error. If medicinal chemists can alter the portions of the statin scaffold that permit RyR1 engagement, the class may retain its lipid-lowering power while becoming less likely to trigger calcium dysregulation in muscle tissue.
A single structural interaction can explain why a medication that protects the heart sometimes harms skeletal muscle.
Why the finding matters for millions taking statins
More than 200 million people worldwide use statins. Most tolerate them well, and the cardiovascular benefit remains substantial. Even so, muscle symptoms are common enough to alter adherence, and discontinuation can strip away the protection that makes these agents so valuable in the first place. For clinicians, the central challenge has been balancing a proven reduction in cardiovascular events against a side effect profile that can be difficult to dismiss when patients describe daily pain, cramping, or weakness.
The new mechanism offers a plausible reason those complaints arise in at least some patients. Calcium is not a passive bystander in muscle physiology; it is the signal that orchestrates contraction and relaxation. When calcium leaks continuously through an open RyR1 channel, the muscle fiber is forced into a state of biochemical strain. Over time, that instability can plausibly translate into soreness, impaired function, and, in rare circumstances, serious muscle damage.
The study also explains why symptoms may vary from person to person. If the interaction between a statin and RyR1 depends on molecular fit, then differences in drug structure, dose, tissue susceptibility, and individual biology could influence who develops symptoms and how severe they become. The paper does not provide a clinical test for predicting intolerance, but it does provide the first detailed structural map of a process that has remained frustratingly obscure.
Dr. Steven Molinarolo, the lead author and a postdoctoral researcher in UBC’s department of biochemistry and molecular biology, said the team was able to see “almost atom by atom” how statins latch onto the channel. That level of resolution is not just a technical achievement. It creates a blueprint for safer cholesterol therapy.
The high-resolution work was made possible through the macromolecular cryo-electron microscopy facility at UBC’s faculty of medicine, where the team could examine the protein in enough detail to trace how the molecules interact within the channel pocket. The study was published in Nature Communications and frames statin muscle toxicity as a tractable structural problem rather than an unavoidable class effect.
For patients already on therapy, the immediate bedside message does not change overnight: statins remain essential medications for many people at elevated cardiovascular risk. But the path forward is clearer. Future agents may be designed to avoid RyR1 binding altogether, and that could make statin therapy easier to sustain for patients who have struggled with muscle adverse effects.
The current data stop at mechanism, not treatment. No new statin has emerged from this paper, and no clinical trial has yet shown that modifying this calcium-channel interaction will eliminate myalgia in practice. What the research does deliver is a rare level of molecular precision around a common adverse effect, and that precision may be enough to shape the next generation of cholesterol-lowering drugs.